Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis

Yang, Hsin Yi; Tzeng, Ya Hui; Chai, Chiah Yang; Hsieh, An Tsz; Chen, Jiun‐Rong; Chang, Le Shin; Yang, Shwu Huey

doi:10.1016/j.nut.2010.09.004

Cited by 53 publications

(43 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, increased consumption of dietary soy protein is associated with decreased cardiovascular disease, type 2 diabetes, and NAFLD [29–31]. Here, we demonstrate that dietary soy protein in the obese, hyperphagic OLETF rat decreased hepatic steatosis, lowered lipid species known to be bioactive (DAGs), changed microbiota populations, induced evidence of alterations in bile acid signaling, and improved cholesterol homeostasis compared with a milk protein source diet.…”

Section: Discussionmentioning

confidence: 59%

Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats

Panasevich

Schuster

Phillips

et al. 2017

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

Soy protein is effective at preventing hepatic steatosis; however, the mechanisms are poorly understood. We tested the hypothesis that soy versus dairy protein-based diet would alter microbiota and attenuate hepatic steatosis in hyperphagic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Male OLETF rats were randomized to “Western” diets containing milk protein isolate (MPI), soy protein isolate (SPI), or 50:50 MPI/SPI (MS) (n=9–10/group; 21% kcal protein) for 16 weeks. SPI attenuated (P<0.05) fat mass and percent fat by ~10% compared with MS, but not compared with MPI. Serum TBAR and total and LDL-cholesterol concentrations were lower (P<0.05) with dietary SPI versus MPI and MS. Histological hepatic steatosis was lower (P<0.05) in SPI compared with MPI or MS. Lipidomic analyses revealed reductions (P<0.05) in hepatic diacylglycerols but not triacylglycerols in SPI compared with MPI, which was associated with lower hepatic de novo lipogenesis (ACC, FAS, and SCD-1 protein content, and hepatic 16:1 n-7 and 18:1 n-7 PUFA concentrations) (P<0.05) compared with MPI and MS; however, MPI displayed elevated hepatic mitochondrial function compared with SPI and MS. Fecal bacterial 16S rRNA analysis revealed SPI-intake elicited increases (P<0.05) in Lactobacillus and decreases (P<0.05) in Blautia and Lachnospiraceae suggesting decreases in fecal secondary bile acids in SPI rats. SPI and MS exhibited greater (P<0.05) hepatic Fxr, Fgfr4, Hnf4a, HmgCoA reductase and synthase mRNA expression compared with MPI. Overall, dietary SPI compared with MPI decreased hepatic steatosis and diacylglycerols, changed microbiota populations, and altered bile acid signaling and cholesterol homeostasis in a rodent model of obesity.

show abstract

Section: Discussionmentioning

confidence: 59%

Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats

Panasevich

Schuster

Phillips

et al. 2017

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

show abstract

“…This effect is associated with an increase in cholesterol efflux, which stimulates the secretion of adiponectin and eliminates free fatty acids in the liver. In a NASH rat model, administration of soy protein lowered the plasma cholesterol concentrations and body fat accumulation, decreased hepatic lipid depots of TAGs and cholesterol, and decreased the lipid peroxide concentration; increases in superoxide dismutase and catalase activity were also noted in treated mice [47]. Soy-derived glucocerebroside has been shown to exert a liver-protective effect and to alleviate NASH in animal models [48,49].…”

Section: Discussionmentioning

confidence: 99%

Oral Administration of CardioAid and Lunasin Alleviates Liver Damage in a High-Fat Diet Nonalcoholic Steatohepatitis Model

et al. 2017

View full text Add to dashboard Cite

Background: Several of the drugs in development for treatment of nonalcoholic steatohepatitis (NASH) target liver fibrosis or have side effects that prohibit their long-term use in patients with mild to moderate disease. Lunasin is a soy-derived peptide with anti-inflammatory properties. ADM's CardioAid™ is a plant sterol extract that exerts cholesterol- and triacylglycerol-lowering effects. Aim: To determine the immunomodulatory effects of CardioAid and lunasin in a high-fat diet (HFD) animal model of NASH. Methods: C57BL/6 mice on an HFD were orally administered CardioAid or lunasin for 25 weeks. The effects on the immune system, liver function, insulin resistance and lipid profile were studied. Results: Treatment with CardioAid and lunasin was associated with a significant decrease in the CD4/CD8 ratio and an increase in CD4+CD25+ lymphocytes. A decrease in interleukin 1-alpha serum levels and an increase in transforming growth factor beta serum levels were noted. These were associated with alleviation of liver damage as indicated by a significant decrease in liver enzymes and improvement in the histological nonalcoholic fatty liver disease activity score (NAS). Decreases in both serum triglyceride and serum glucose levels were observed in treated mice. A decrease in total body fat measured by EchoMRI was also observed in treated mice. Conclusions: CardioAid and lunasin exerted hepatoprotective and glucose-protective effects in an HFD NASH model. These data and the high-safety profiles of CardioAid and Lunasin support their use in patients in the early stages of NASH to prevent deterioration due to the disease.

show abstract

“…The interest on functional foods has increased due to several benefits in a diversity of illness [3]. Particularly, it has been reported that some seed protein isolates from soybean, barley, amaranth, quinoa, and linseed have a positive biological activity against several metabolic disorders, as shown in studies in disease models such as diet-induced obesity [4], streptozotocin-induced diabetes [5,6], proliferation of cancer cells [7] and alcohol-induced cirrhosis [8].…”

Section: Introductionmentioning

confidence: 99%

Amaranth Protein Improves Lipid Profile and Insulin Resistance in a Diet-induced Obese Mice Model

Escobedo-Moratilla¹,

Velarde‐Salcedo²,

Magaña-Hernández³

et al. 2017

JFNR

View full text Add to dashboard Cite

Amaranth has been claimed as functional food, but its function on obesity-related disorder is not fully known. The aim of this study was to analyse the effect of amaranth protein intake on blood lipids profile and insulin resistance in diet-induced obese mice. The effect of soybean protein was also analysed for comparative purposes. C57BL-6 mice were fed for eight weeks with regular or high fat diet. Amaranth or soybean protein isolates (10 mg/kg) were supplied via oral administration. Changes in body weight, adipose tissue, total cholesterol, triglycerides, insulin, a glucose tolerance test, as well as the expression of lipid metabolism-related genes were measured. Our results have shown that amaranth protein induces a decrease in plasma insulin in mice fed with a regular diet, whereas a decrease in triglycerides was observed in mice fed with high fat diet. Furthermore, down-regulation of Tnf-α and Res, suggested the inhibition of inflammation state. The present study demonstrates that amaranth protein, but not soybean protein, improves the obese mice health, and the hormonal modulation (Lep, Fasn, Lpl) could lead to new mechanism of action by which amaranth consumption exerts its beneficial health effect.

show abstract

Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis

Cited by 53 publications

References 25 publications

Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats

Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats

Oral Administration of CardioAid and Lunasin Alleviates Liver Damage in a High-Fat Diet Nonalcoholic Steatohepatitis Model

Amaranth Protein Improves Lipid Profile and Insulin Resistance in a Diet-induced Obese Mice Model

Contact Info

Product

Resources

About